Medicine guide
VITRAKVI 25 mg
As listed in the register: VITRAKVI 25 mg, gélule
· gélule
- Prescription only
- Active substance
- Sulfate De Larotrectinib
- Made by
- BAYER AG (ALLEMAGNE)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Details
| Made by | BAYER AG (ALLEMAGNE) |
|---|---|
| Active substance | Sulfate De Larotrectinib |
| Form | gélule |
| Route | orale |
| Dispensing (as stated by the register) | médicament nécessitant une surveillance particulière pendant le traitement · prescription réservée aux spécialistes et services ONCOLOGIE MEDICALE · prescription hospitalière · liste I · prescription réservée aux médecins compétents en CANCEROLOGIE |
| Marketed | Yes, according to the register |
| Reinforced monitoring | Yes — under reinforced monitoring, according to the register |
| Authorisation procedure | Procédure centralisée |
| EU number | EU/1/19/1385 |
| Name in the register | VITRAKVI 25 mg, gélule |
| Packs | 1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 56 gélule(s) |
| CIS | 67022406 |
| CIP13 | 3400930187999 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.